For the quarter ended December 2025, Equity Residential (EQR) reported revenue of $781.91 million, up 2% over the same period last year. EPS came in at $1.03, compared to $1.10 in the year-ago quarter.The reported revenue represents a surprise of -0.94% over the Zacks Consensus Estimate of $789.34 million. With the consensus EPS estimate being $1.04, the EPS surprise was -0.74%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determ ...

Wall Street analysts expect Becton Dickinson (BDX) to post quarterly earnings of $2.82 per share in its upcoming report, which indicates a year-over-year decline of 17.8%. Revenues are expected to be $5.15 billion, down 0.4% from the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.8% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Ahead of a company's earn ...

Wall Street analysts expect Tapestry (TPR) to post quarterly earnings of $2.20 per share in its upcoming report, which indicates a year-over-year increase of 10%. Revenues are expected to be $2.31 billion, up 5.2% from the year-ago quarter.The current level reflects an upward revision of 5.4% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Prior to a company's e ...

The upcoming report from Mettler-Toledo (MTD) is expected to reveal quarterly earnings of $12.76 per share, indicating an increase of 2.8% compared to the year-ago period. Analysts forecast revenues of $1.1 billion, representing an increase of 5.4% year over year.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Prior to a co ...

BrightView Holdings (BV) reported $614.7 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 2.6%. EPS of -$0.01 for the same period compares to $0.04 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $587.85 million, representing a surprise of +4.57%. The company delivered an EPS surprise of -300%, with the consensus EPS estimate being $0.01.While investors scrutinize revenue and earnings changes year-over-year and how they compare wit ...

Analysts on Wall Street project that BCE (BCE) will announce quarterly earnings of $0.46 per share in its forthcoming report, representing a decline of 17.9% year over year. Revenues are projected to reach $4.71 billion, increasing 2.7% from the same quarter last year.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Ahead of a company's earnings disclosure ...

Core Viewpoint - MGIC Investment reported a slight decline in revenue for the quarter ended December 2025, with a year-over-year decrease of 1.8% despite a positive EPS surprise [1] Financial Performance - Revenue for the quarter was $297.8 million, which was below the Zacks Consensus Estimate of $306.65 million, resulting in a surprise of -2.89% [1] - The EPS for the quarter was $0.75, compared to $0.72 a year ago, indicating a year-over-year increase [1] - The company delivered an EPS surprise of +3.21%, with the consensus EPS estimate being $0.73 [1] Key Metrics - Net investment income was reported at $61.61 million, slightly below the average estimate of $62.37 million, reflecting a year-over-year change of +0.5% [4] - Net premiums earned were $236.02 million, which was lower than the estimated $243.82 million, showing a year-over-year decline of -2.2% [4] - Other revenue was reported at $0.16 million, significantly below the estimated $0.46 million, representing a year-over-year decrease of -65% [4] Stock Performance - MGIC shares have returned -7.7% over the past month, contrasting with the Zacks S&P 500 composite's increase of +0.7% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Tyson Foods (TSN) reported $14.31 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 5.1%. EPS of $0.97 for the same period compares to $1.14 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $14.12 billion, representing a surprise of +1.36%. The company delivered an EPS surprise of -3.96%, with the consensus EPS estimate being $1.01.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ...

Wall Street analysts expect Yum Brands (YUM) to post quarterly earnings of $1.78 per share in its upcoming report, which indicates a year-over-year increase of 10.6%. Revenues are expected to be $2.47 billion, up 4.4% from the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.2% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company's earnings rele ...

Core Viewpoint - Amgen (AMGN) is expected to report quarterly earnings of $4.74 per share, a decline of 10.7% year-over-year, with revenues projected at $9.46 billion, reflecting a 4.2% increase compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised upward by 0.1% over the past 30 days, indicating analysts have adjusted their projections positively [2]. - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between these revisions and short-term stock price performance [3]. Revenue and Product Sales Projections - Analysts predict 'Revenue- Other revenues' will reach $402.12 million, an increase of 8.7% from the prior-year quarter [5]. - 'Revenue- Product sales' is expected to be $9.04 billion, reflecting a 3.7% increase year-over-year [5]. - 'Product Sales- Vectibix- Total' is projected at $279.69 million, indicating a 13.7% increase from the previous year [5]. Specific Product Sales Estimates - 'Product Sales- Enbrel- Total' is estimated at $649.46 million, showing a significant decline of 36% year-over-year [6]. - 'Product Sales- Neulasta- U.S.' is projected at $56.02 million, down 22.2% from the year-ago quarter [6]. - 'Product Sales- Neulasta- ROW' is expected to reach $19.40 million, reflecting a 25.4% decline [6]. - 'Product Sales- BLINCYTO- ROW' is estimated at $152.62 million, an increase of 12.2% year-over-year [7]. - 'Product Sales- Repatha- U.S.' is projected at $442.32 million, indicating a substantial increase of 40.4% from the previous year [7]. - 'Product Sales- Repatha- ROW' is expected to be $360.19 million, reflecting a 23.8% increase [8]. - 'Product Sales- BLINCYTO- U.S.' is projected at $287.58 million, indicating a 17.4% increase [8]. - 'Product Sales- KYPROLIS- U.S.' is expected to reach $228.82 million, showing a slight decline of 3% year-over-year [8]. - 'Product Sales- KYPROLIS- ROW' is projected at $130.37 million, reflecting a 4.1% decline [9]. Stock Performance - Amgen shares have increased by 4.6% over the past month, outperforming the Zacks S&P 500 composite, which has risen by 0.8% [9].